A multicenter, rand[omised], double-blind, titration study to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin vs atorvastatin in hypercholestrolemic pts [patients] at moderately high risk for CHD [coronary heart disease] not adequately controlled on atorvastatin 20 mg

Trial Profile

A multicenter, rand[omised], double-blind, titration study to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin vs atorvastatin in hypercholestrolemic pts [patients] at moderately high risk for CHD [coronary heart disease] not adequately controlled on atorvastatin 20 mg

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Atorvastatin; Ezetimibe
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2008 Results published in the Americal Journal of Cardiology.
    • 01 Dec 2008 Primary endpoint 'Low density lipoprotein cholesterol level' has been met according to results published in the American Journal of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top